Fmr LLC Aura Biosciences, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Fmr LLC holds 230,451 shares of AURA stock, worth $2.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

230,451

Previous 294,654 21.79%

Holding current value

$2.51 Million

Previous $2.31 Million 24.69%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$6.81 - $7.89 $437,222 - $506,561	-64,203 Reduced 21.79%	230,451 $1.74 Million
Q1 2024 May 13, 2024	SELL	$7.09 - $9.24 $442,281 - $576,400	-62,381 Reduced 17.47%	294,654 $2.31 Million
Q4 2023 Feb 13, 2024	SELL	$7.02 - $11.98 $10,712 - $18,281	-1,526 Reduced 0.43%	357,035 $3.16 Million
Q3 2023 Nov 13, 2023	SELL	$8.97 - $12.38 $672 - $928	-75 Reduced 0.02%	358,561 $3.22 Million
Q2 2023 Aug 11, 2023	BUY	$8.51 - $13.33 $15,224 - $23,847	1,789 Added 0.5%	358,636 $4.43 Million
Q1 2023 May 11, 2023	SELL	$8.88 - $12.11 $3.3 Million - $4.5 Million	-371,550 Reduced 51.01%	356,847 $3.31 Million
Q4 2022 Feb 13, 2023	BUY	$9.86 - $14.59 $1.23 Million - $1.82 Million	124,636 Added 20.64%	728,397 $7.65 Million
Q3 2022 Nov 10, 2022	BUY	$13.1 - $20.34 $3,799 - $5,898	290 Added 0.05%	603,761 $10.9 Million
Q2 2022 Aug 12, 2022	BUY	$12.37 - $21.86 $1.35 Million - $2.39 Million	109,362 Added 22.13%	603,471 $8.55 Million
Q1 2022 May 13, 2022	BUY	$15.94 - $23.34 $363,575 - $532,362	22,809 Added 4.84%	494,109 $10.9 Million
Q4 2021 Feb 14, 2022	BUY	$14.76 - $24.89 $6.96 Million - $11.7 Million	471,300 New	471,300 $8 Million

Others Institutions Holding AURA

# of Institutions

Shares Held

40.3M

Call Options Held

800

Put Options Held

1.8K

View Full List

About Aura Biosciences, Inc.

Ticker AURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,273,600
Market Cap $318M
Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...

More about AURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account